Cleveland Clinic Biologic Therapies Summit IX 2021
Format:28 videos, size: 8.69 GB
Course Audience: rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians
Overview:
Biologic Therapies Summit IX 2021 returns to in-person learning, bringing together world leaders in immune-based therapies and addressing cutting-edge topics in immunology and rheumatology. The course begins with a full day devoted to vasculitis, including key issues in the differential diagnosis of vasculitis, CNS vasculitis, ANCA-associated vasculitis, and organ-specific issues in vasculitis. The Biologic Therapies Summit X offers six sessions over two days, and kicks off with a half-day session featuring talks on CAR T-cell therapy, irAEs, precision medicine and the next generation of JAK inhibitors for IMIDs, and advances in complement biology and therapy. We take a deep dive into rheumatoid arthritis, AS, PsA and SpA in the afternoon. Day two addresses infections, COVID-19, co-morbidities with IMIDs, including ILD and cardiovascular risk in immune-mediated diseases, and lupus. We wrap up the Summit with a session devoted to pain management, as we welcome physician, writer, and clinical researcher, Haider Warraich, MD, for an exploration of the social and scientific fundamentals of pain.
Why Attend?
- Join for a full-day devoted to hot topics in Vasculitis
- Hear from internationally renowned experts in the fields of immunology and rheumatology
- Expand and enhance decision-making skills for appropriate use of biologic therapies in highly complex clinical situations
- Participate in our APP workshop, included with course registration
By Attending, You Will Be Able To:
- Describe and critically appraise the immunologic mechanisms of action for targeted therapies and targeted synthetic therapies as they apply to efficacy and safety across the spectrum of immune-mediated inflammatory diseases including PsA, SpA, RA, SLE and vasculitis.
- Outline how precision medicine has been used to manage immune-related adverse events.
- Define advances in complement with rheumatic and immunologic diseases.
- Summarize evidence on COVID-19 and vaccinations and their effects on patients with immune-mediated inflammatory diseases, and describe the implications for clinical practice.
- Critically appraise how Long COVID presents in patients with immune-mediated inflammatory diseases.
- Evaluate comorbidities such as cardiovascular risk and complications associated with immune-mediated diseases.
- Define the clinical differences between type 1 and type 2 lupus.
Who Should Attend?
The Summit is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, pharmacists, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.
A Vasculitis Case Presentation (Video MP4 Format)
Advances in Pulmonary Aspects of Progressive Systemic Sclerosis (Video MP4 Format)Advances in understanding of the immunobiology of COVID-19 – at 1.5 years (Video MP4 Format)Are There Factors That Can Guide Treatment Decisions in Newly Diagnosed and Relapsing Takayasu Arteritis (Video MP4 Format)Clinical Approach to Diagnosis and Treatment of Cytokine Storm in Rheumatic Diseases (Video MP4 Format)COVID-19 and Autoimmunity (Video MP4 Format)Cytokine Storm Where Rheumatologists, Oncologists, and ID Meet (Video MP4 Format)Difficult Rheumatoid Arthritis (Video MP4 Format)Does Plasma Exchange Have a Role in Patients With ANCA-Associated Vasculitis and Rapidly Progressive Glomerulonephritis or Pulmonary Hemorrhage (Video MP4 Format)Endocarditis and the Rheumatologist (Video MP4 Format)Evolving Treatment Strategies in Psoriatic Arthritis (PsA) How Do We Choose (Video MP4 Format)How do I Recognize and Treat the VEXAS Syndrome (Video MP4 Format)How Does the Treatment of Beh‡et’s Disease Differ Based on Disease Manifestations (Video MP4 Format)Is There Still a Role for Conventional Immunosuppressive Agents in ANCA-Associated Vasculitis (Video MP4 Format)JAK Inhibitors for Rheumatoid Arthritis Focus on Safety (Video MP4 Format)Maintenance Rituximab in ANCA-Associated Vasculitis Dose, Frequency, and Duration – How Do We Decide (Video MP4 Format)MANAGING IMMUNOMODULATING THERAPIES AND IMMUNOCOMPROMISED PATIENTS DURING THE COVlD-l9 PANDEMIC (Video MP4 Format)Non-Radiographic Axial Spondyloarthritis New Name to an old Disease (Video MP4 Format)Psoriatic Arthritis- Different treatment responses of skin and joint manifestations (Video MP4 Format)Safety of Biologics and JAK Inhibitors (Mycobacterial Infections) (Video MP4 Format)Targeted Theories in irAES (Video MP4 Format)Vaccinating Patients with Immune Mediated Inflammatory Disease (Video MP4 Format)Vasculitis Treatment Case Presentation (Video MP4 Format)What Are the Options for Treating CNS Vasculitis (Video MP4 Format)What Dose and Duration of Glucocorticoids Should be Used in ANCA-Associated Vasculitis (Video MP4 Format)What’s New in SpA Case Presentation (Video MP4 Format)When Should Biologic Agents be Considered in Eosinophilic Granulomatosis With Polyangiitis (Video MP4 Format)When Should Biologic Agents be Introduced in Giant Cell Arteritis and For How Long Should They Be Given (Video MP4 Format)